Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Docetaxel in combination with Pertuzumab and Trastuzumab in patients with Invasive Breast Carcinoma.

Statements

Source and description
Perjeta (pertuzumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.
Perjeta (pertuzumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and docetaxel for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
Phesgo (pertuzumab / trastuzumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.
Phesgo (pertuzumab / trastuzumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
Perjeta (pertuzumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Phesgo (pertuzumab and trastuzumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with docetaxel for the treatment of patients with HER2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Pertuzumab/Trastuzumab (Phesgo) and DOCEtaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) in combination with docetaxel for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
Pertuzumab,Trastuzumab and DOCEtaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and docetaxel for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
Pertuzumab and Trastuzumab and Chemotherapy Therapy - 21 day cycle. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. According to the EMA product information for this indication, this indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.